SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Skye Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.53−0.02 (-1.29%)
Close on Oct 19, 2026
- Market cap
- $60.73M
- P/E (TTM)
- –
- Dividend yield
- –
Skye Bioscience statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Market Cap | $54.19M | $164.85M |
| Enterprise Value | $44.13M | $87.06M |
Income (trailing twelve months)
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Operating Income | -$51.90M | -$21.44M |
| Pretax Income | -$50.49M | -$14.45M |
| Net Income | -$50.49M | -$22.46M |
| EBITDA | -$51.21M | -$16.91M |
| EPS (Diluted) | -$1.27 | -$0.83 |
Returns
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Return on Equity (ROE) | -233.9% | -53.1% |
| Return on Assets (ROA) | -159.8% | -41.0% |
Balance sheet
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $10.06M | $62.42M |
| Net Cash (Debt) | $10.06M | $15.68M |
| Net Cash Per Share | $0.28 | $0.66 |
| Equity (Book Value) | -$497.31K | $48.79M |
| Book Value Per Share | -$0.01 | $1.36 |
| Tangible Book Value | -$497.31K | $23.06M |
| Working Capital | -$572.22K | $75.77M |
Financial position
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Current Ratio | 0.95 | 3.30 |
| Quick Ratio | 0.87 | 2.39 |
| Interest Coverage | -9439.02 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Operating Cash Flow | -$38.81M | -$12.35M |
| Capital Expenditures | $0 | -$1.06M |
| Free Cash Flow | -$38.81M | -$20.28M |
| FCF Per Share | -$1.10 | -$0.42 |
Efficiency
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Profits Per Employee | -$4.21M | -$703.34K |
| Employee Count | 12 | 74 |
Dividends and yields
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Earnings Yield | -93.2% | -22.7% |
| FCF Yield | -71.6% | -9.07% |
Shares
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Shares Outstanding | 35,421,400 | 58,179,650 |
| Shares Change (YoY) | 0.38% | 11.1% |
| Shares Change (QoQ) | 0.05% | 0.54% |
Taxes
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Income Tax | $3.40K | $91.50K |
Scores
| Measure | Skye Bioscience | Industry median |
|---|---|---|
| Altman Z-Score | -39.43 | -0.24 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Skye Bioscience's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.